Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPAS1 | Q99814 | 12/20 | 0.46 |
| ▸ | VEGFA | P15692 | 3/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | TTR | P02766 | 1/20 | 0.37 |
| ▸ | PPOX | P50336 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3488905 | 0.92 | SIRT5 (0.38) | EPAS1VEGFATDP1MEN1TTR | |
| SCHEMBL3489487 | 0.88 | TSHR (0.36) | MEN1KMT2APPARGSIRT5 | |
| SCHEMBL3487205 | 0.88 | MAPT (0.38) | MEN1KMT2A | |
| SCHEMBL27782512 | 0.86 | EPAS1 (0.43) | EPAS1VEGFATDP1HIF1AMEN1 | |
| SCHEMBL3487913 | 0.86 | HSPB1 (0.47) | TDP1MEN1KMT2A | |
| SCHEMBL3487628 | 0.85 | MAPT (0.45) | EPAS1TDP1MEN1KMT2A | |
| SCHEMBL3487453 | 0.85 | SIRT5 (0.47) | TDP1MEN1KMT2ASIRT5 | |
| SCHEMBL3489428 | 0.85 | SOS1 (0.39) | TDP1HIF1AMEN1TTRPPOX | |
| SCHEMBL3487276 | 0.83 | TSHR (0.38) | TDP1MEN1TTRPPOXKMT2A | |
| SCHEMBL3488382 | 0.81 | EPAS1 (0.41) | EPAS1VEGFAHIF1APPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2138484-B1 | FUSED BICYCLIC HETEROARYL DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2015-08-26 | — | — | EP | disclosed |
| US-20100048564-A1 | FUSED BICYCLIC HETEROARYL DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-02-25 | — | — | US | disclosed |
| EP-2138484-A1 | FUSED BICYCLIC HETEROARYL DERIVATIVES | Daiichi Sankyo Company, Limited (JP) | 2009-12-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048564-A1 | FUSED BICYCLIC HETEROARYL DERIVATIVE | PPARG, GPR119, PPARA | EPAS1 2293/4885VEGFA 2723/4885TDP1 4745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.